Additional Ehave Inc News Today

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Ehave Prepares to Launch Ketamine Clinical Trials Using Brain Scientific’s Brain Mapping Technology EhaveApril 16, 2021 GMT MIAMI, April 16, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today plans to launch brain mapping ketamine clinical trials using Brain Scientific technolog...

About Ehave, Inc. Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatic...

Medical records platform for psychedelic mental health to be available February 1 as a Plugin to the Ehave Dashboard.

News Category Global Banking & Finance Reviews Ehave, Inc. Closes 20/20 Global Transaction, Mycotopia Therapy Now Operating as a Publicly Traded Company with Intent to Focus on Psychedelic Sector Ehave, Inc. Closes 20/20 Global Transaction, Mycotopia Therapy Now Operating as a Publicly Traded Company with Intent to Focus on Psychedelic Sector MIAMI, Jan. 20, 2021 — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in digital therapeutics, announced today the Company has closed the t...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

MIAMI, Jan. 11, 2021 -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in digital therapeutics, announced it has licensed revolutionary AI to unlock

[December 28, 2020] Ehave, Inc. Announces Repositioning of Mycotopia Therapies to Maximize Shareholder Value MIAMI, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in digital therapeutics and developer of KetaDASH, a home delivery platform for patients who have been prescribed Ketamine infusions, announced today the Companys Board of directors has elected to sell 100% of its Mycotopia Therapies subsidiary to 20/20 Global Inc. (OTC Pink: TWGL) ...

Ehave, Inc. Announces KetaDASH for Ketamine Home Delivery and Purchase of Curedash Assets Ehave, Inc. Announces KetaDASH for Ketamine Home Delivery and Purchase of Curedash Assets MIAMI, Dec. 16, 2020 — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients, today announced KetaDASH www.ketadash.com, an Intravenous (IV) based, home delivery platform for patients who have been prescribed Ketamine. Eha...